Redhill Biopharma Ltd. (NASDAQ:RDHL) management will conduct a conference call for 12th November 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.redhillbio.com
To participate in the conference call, local and international callers can dial +1-877-870-9135 or +1-646-741-3167 Outside U.S., and the passcode is 4549918
Earnings Expectation
Redhill Biopharma Ltd. is set to announce third quarter earning results on Thursday 12th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, RDHL to report 3Q20 loss of $ 0.16 per share. For the full year, analysts anticipate top line of $ 82.55 million, while looking forward to loss of $ 0.66 per share bottom line.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The companys clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohns disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
